Blood test tracking for immunotherapy in stage 4 melanoma
Part of Cancer, Skin clinical trials.
This trial is testing a simple blood test (liquid biopsy) to track how well melanoma responds to immunotherapy. It might help doctors decide if treatment is working or needs to be changed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have melanoma that has spread (stage 4) or cannot be surgically removed (stage 3).
- Your cancer has gotten worse on scans within the last month.
- You have already had at least 1 round of immunotherapy (a type of treatment that helps your immune system fight cancer).
- You are 16 years old or older.
- You do not have HIV, hepatitis B, or hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
This trial studies whether a simple blood test can predict how well your immune system will respond to immunotherapy (such as Keytruda or Opdivo). You may qualify if you have lung cancer (NSCLC) or advanced melanoma and are about to start this type of treatment for the first time.
This study checks how your immune system behaves (through an immune testing process) to see if it can predict how well advanced melanoma will respond to checkpoint inhibitor treatment. It may help doctors choose the right treatment sooner, without guessing.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
This trial studies a very sensitive blood test to detect melanoma-related genetic changes in people with BRAF V600E. It may help track the disease more closely and guide care in advanced or high-risk situations.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.